Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. reports developments for a clinical-stage biotechnology business focused on small-molecule therapeutics for serious viral diseases. Its recurring updates center on investigational antiviral candidates for herpes simplex virus, hepatitis delta virus and hepatitis B virus, including helicase-primase inhibitors ABI-5366 and ABI-1179, the HDV entry inhibitor ABI-6250 and the HBV capsid assembly modulator ABI-4334.
Company news also covers clinical data presentations, financial results, research and collaboration revenue, the Gilead collaboration and licensing activity, and equity financing transactions that support pipeline development.
Assembly Biosciences (Nasdaq: ASMB) will present topline Phase 1a data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, at the EASL Congress 2026 in Barcelona on May 27, 2026.
The randomized, blinded study evaluates safety, pharmacokinetics and pharmacodynamic activity in healthy participants.
Assembly Biosciences (Nasdaq: ASMB) announced that chief medical officer Anuj Gaggar, MD, PhD, will present at the BofA Securities 2026 Global Health Care Conference at 4:35 p.m. PT on May 13, 2026. A live webcast and replay will be available via the company’s investor relations website.
Assembly Biosciences (Nasdaq: ASMB) reported Q1 2026 results and program updates on May 7, 2026. Key development milestones include completed Phase 1b follow-up for ABI-5366 and ABI-1179, completed chronic toxicology for ABI-6250, and an expected Phase 2 start for ABI-6250 in Q4 2026.
Financials: $226.6M cash and marketable securities at March 31, 2026, projected runway into 2028; collaborative revenue with Gilead was $8.2M in Q1; net loss attributable to common stockholders was $9.1M (loss per share $0.54).
Assembly Bio (Nasdaq: ASMB) announced that positive Phase 1b data for two investigational HSV helicase-primase inhibitors, ABI-5366 and ABI-1179, will be presented at ESCMID Global 2026 in Munich, April 17-21, 2026.
ABI-5366 is selected for an oral presentation (April 20, 2026) and two posters (April 18, 2026). ABI-1179 is a late-breaker poster (April 21, 2026). Posters will be posted on the company website. Both candidates are investigational and exclusively licensed to Gilead for further development.
Assembly Biosciences (Nasdaq: ASMB) reported year-end 2025 results and pipeline progress on March 19, 2026. Key items include a $35 million net option fee from Gilead for the HPI program, $248.1M cash and securities, collaboration revenue of $72.3M, and a net loss of $6.1M for 2025.
Major development milestones: positive Phase 1b data for ABI-5366 and ABI-1179, initiation plans for ABI-6250 Phase 2 by end-2026, and regained rights to ABI-4334 after Gilead declined its option.
Assembly Biosciences (NASDAQ:ASMB) and Gilead Sciences announced Gilead exercised its option to exclusively license Assembly Bio’s HSV helicase-primase inhibitor programs, ABI-1179 and ABI-5366, for recurrent genital herpes on December 22, 2025. Assembly Bio will receive a $35 million payment reflecting an option fee net of prior accelerated funding. Gilead gains sole U.S. development and commercialization rights; Assembly Bio remains eligible for up to $330 million in milestones plus tiered royalties and a U.S. opt-in to share 40% of costs and profits.
Both candidates showed positive Phase 1b antiviral and safety data supportive of once-weekly oral dosing.
Assembly Bio (Nasdaq: ASMB) reported positive interim Phase 1b results for two long-acting HSV helicase-primase inhibitor candidates, ABI-1179 (weekly oral) and ABI-5366 (monthly and weekly oral regimens), dated Dec 8, 2025.
Key findings: 50 mg weekly ABI-1179 showed a 98% reduction in HSV-2 shedding, > 99% reduction in high viral load swabs and 91% reduction in virologically confirmed genital lesion rate vs placebo over 29 days; ABI-5366 monthly cohort showed 76% shedding and 88% lesion rate reductions. Both candidates were generally well tolerated and PK supports weekly and potentially monthly dosing.
Assembly Biosciences (Nasdaq: ASMB) reported Q3 2025 results and program updates on Nov 10, 2025. Key clinical highlights include positive Phase 1b interim results for ABI-5366 showing significant reductions in HSV-2 shedding and genital lesions, and Phase 1a data for ABI-6250 supporting once-daily dosing and progression to Phase 2. Enrollment completed for ABI-5366 and two ABI-1179 cohorts; an HSV data readout is now expected by year-end and a Phase 2 start for ABI-5366 is anticipated mid-2026.
Financials: the company raised $175M in equity, held $232.6M cash at Sept 30, 2025 (runway into late 2027), reported Q3 revenue from Gilead collaboration of $10.8M, R&D $16.6M, and net loss of $9.2M.
Assembly Biosciences (Nasdaq: ASMB) presented positive Phase 1b data for its next‑generation capsid assembly modulator ABI‑4334 at AASLD The Liver Meeting® on Nov 7, 2025.
The randomized, blinded Phase 1b evaluated oral once‑daily 150 mg and 400 mg doses for 28 days in predominantly HBeAg‑negative chronic hepatitis B patients. ABI‑4334 was reported as well tolerated at both doses, produced multi‑log declines in HBV DNA and pgRNA, and achieved exposures multiple‑fold above levels anticipated to inhibit cccDNA formation. As expected for the population and short dosing interval, no reductions in HBsAg were observed. Under a collaboration, Gilead has a post‑study option to obtain an exclusive license for further development of ABI‑4334.
Assembly Biosciences (Nasdaq: ASMB) will participate in two investor conference fireside chats in October–November 2025.
Anuj Gaggar, MD, PhD, chief medical officer, will appear in a pre-recorded fireside chat available on demand beginning October 21, 2025 at 7:00 AM ET during the H.C. Wainwright Liver Disease Virtual Conference.
Jason Okazaki, CEO and president, and Dr. Gaggar will present a live fireside chat on November 12, 2025 at 11:00 AM ET at the Guggenheim 2nd Annual Healthcare Innovation Conference. Webcasts and replays will be available via the company's Events and Presentations page.